The article evaluates the state of the biotechnology industry within the nation of Ireland. While the company Elan announced that it would be eliminating 230 positions that exist largely at its biological manufacturing and fill-finish facilities, this is not indicative of the industry as a whole. The success of the firm Opsona Therapeutics is examined, and the availability of venture capital is discussed.